title: Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
abstract: BACKGROUND
  A life-attenuated vaccine aimed at preventing herpes zoster (HZ) and its main complication, post-herpetic neuralgia (PHN), will soon be available in Europe. The study's objective was to assess the clinical and economic impact of a vaccination program for adults aged 70-79 years in Switzerland.
  
  
  RESULTS
  A vaccination strategy compared to a no-vaccination resulted in lifetime incremental cost-effectiveness ratios (ICERs) of 25,538 CHF (23,646 USD) per QALY gained, 6,625 CHF (6,134 USD) per HZ case avoided, and 15,487 CHF (14,340 USD) per PHN3 case avoided under the third-party payer perspective. Sensitivity analyses showed that the model was most sensitive to the discount rates, HZ epidemiological data and vaccine price used.
  
  
  METHODS
  A Markov model, simulating the natural history of HZ and PHN and the lifetime effects of vaccination, previously developed for the UK was adapted to the Swiss context. The model includes several health states including good health, HZ, PHN, and death. HZ and PHN states reflected pain severity.
  
  
  CONCLUSIONS
  The model predicts clinical and economic benefits of vaccination in the form of fewer HZ and PHN cases and reductions in healthcare resource use. ICERs were within the commonly accepted thresholds in Switzerland, indicating that a HZ vaccination program would be considered a cost-effective strategy in the Swiss setting.
authors: University of Basel, Switzerland.
authors: Thomas D
authors: TD
authors: Szucs
authors: Reto W
authors: RW
authors: Kressig
authors: Manto
authors: M
authors: Papageorgiou
authors: Werner
authors: W
authors: Kempf
authors: Jean-Pierre
authors: JP
authors: Michel
authors: Anton
authors: A
authors: Fendl
authors: Xavier
authors: X
authors: Bresse
references: J Pain. 2005 Jun;6(6):356-63
references: 15943957
references: Pain. 1996 Oct;67(2-3):241-51
references: 8951917
references: Clin J Pain. 2002 Nov-Dec;18(6):350-4
references: 12441828
references: Arch Intern Med. 1995 Aug 7-21;155(15):1605-9
references: 7618983
references: Curr Med Res Opin. 2008 May;24(5):1473-83
references: 18413014
references: Epidemiol Infect. 2009 Jan;137(1):38-47
references: 18466661
references: N Engl J Med. 2005 Jun 2;352(22):2271-84
references: 15930418
references: Clin J Pain. 2007 Jul-Aug;23(6):490-6
references: 17575488
references: Fam Pract. 2002 Oct;19(5):471-5
references: 12356697
references: J Clin Epidemiol. 1998 Aug;51(8):667-76
references: 9743315
references: BMJ. 2000 Sep 30;321(7264):778-9
references: 11009498
references: J Med Virol. 2003;70 Suppl 1:S24-30
references: 12627483
references: J Epidemiol Community Health. 2001 Feb;55(2):123-5
references: 11154251
references: Praxis (Bern 1994). 2001 Mar 29;90(13):539-45
references: 11550619
references: Vaccine. 2007 Nov 28;25(49):8326-37
references: 17980938
references: Pharmacoeconomics. 2005;23(7):639-49
references: 16173156
references: Cost Eff Resour Alloc. 2010 Apr 30;8:7
references: 20433704
references: Vaccine. 2001 Apr 30;19(23-24):3076-90
references: 11312002